From 0d3383a112d64e038a18cf9a502579aeb01d7028 Mon Sep 17 00:00:00 2001
From: Isabell Alexandra Guckes <isabell.guckes@uni-bielefeld.de>
Date: Wed, 25 Sep 2024 16:15:14 +0000
Subject: [PATCH] Update file drug-data.tsx
---
src/data/drug-data.tsx | 2 +-
1 file changed, 1 insertion(+), 1 deletion(-)
diff --git a/src/data/drug-data.tsx b/src/data/drug-data.tsx
index 15dd52a4..655e699e 100644
--- a/src/data/drug-data.tsx
+++ b/src/data/drug-data.tsx
@@ -38,7 +38,7 @@ export const drugdata: (Array<DrugDatensatz>) = [
text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor \n Indications: For CF patients aged 2 years and older with at least one F508del mutation à 85 % of CF patients \n Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]. \n Administration: Oral tablets \n Approval: Approved by the EMA in 2020 "] },
{
title: "Symdeko",
- text: ["Active ingredient(s): Combination of tezacaftor and ivacaftor \n Indications: For CF patients aged 6 years and older with specific mutations in combination with F508del or with two copies of F508del mutation \n Mechanism: Tezacaftor acts as a corrector on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5] \n Administration: Oral tablets \n Approval: Approved by the EMA in 2018"]
+ text: ["Active ingredient(s): Combination of tezacaftor and ivacaftor", "Indications: For CF patients aged 6 years and older with specific mutations in combination with F508del or with two copies of F508del mutation", "Mechanism: Tezacaftor acts as a corrector on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5]", "Administration: Oral tablets", "Approval: Approved by the EMA in 2018"]
},
]
},
--
GitLab